Profiling the Development of Gene Therapies at Rejuvenate Bio
Here is an overview of the groundbreaking work being done at Rejuvenate Bio, a company dedicated to developing gene therapies aimed at improving aging metabolism. Their focus is on altering tissues to produce signal molecules that play a crucial role in aging. While gene therapies are the future of medicine, targeting specific organs or cell types can be challenging and costly. Rejuvenate Bio has found success by using established approaches, such as delivering gene therapies to the liver or injecting the vector directly into fat tissue. This allows cells to produce and release the desired signal molecule, which then travels throughout the body.
The founders of Rejuvenate Bio explain that their approach involves studying successful genetic interventions and transforming them into safe and effective gene therapies for human patients. They have identified three key longevity genes – FGF21, TGFβ-1, and α-klotho – each with proven efficacy and safety profiles. By delivering their FGF21 gene therapy via a specific strain of adeno-associated virus that targets liver tissue, they are able to achieve systemic effects throughout the body.
This innovative approach has shown promising results, particularly in targeting arrhythmogenic cardiomyopathy in mice. By turning the liver into a therapeutic bio factory and overexpressing key signaling proteins, Rejuvenate Bio is revolutionizing the field of gene therapy.
For more information, you can read the full article here: longevity.technology
